gemcitabine has been researched along with pyrazolanthrone in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ammerpohl, O; Griep, U; Grutzmann, R; Janssen, O; Kalthoff, H; Kloppel, G; Pilarsky, C; Saeger, HD; Schniewind, B; Sipos, B; Trauzold, A | 1 |
| Dong, XY; Gou, X; He, WY; Huang, XL; Lin, Y; Xie, XY; Yang, XY; Yin, HB; Zhang, H | 1 |
2 other study(ies) available for gemcitabine and pyrazolanthrone
| Article | Year |
|---|---|
Complementary effects of HDAC inhibitor 4-PB on gap junction communication and cellular export mechanisms support restoration of chemosensitivity of PDAC cells.
Topics: Anthracenes; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Pancreatic Ductal; Caspase 8; Cell Communication; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Enzyme Activation; Gap Junctions; Gemcitabine; Histone Deacetylase Inhibitors; Humans; Pancreatic Neoplasms; Phenylbutyrates; Time Factors; Tumor Cells, Cultured | 2007 |
Activation of a c-Jun N-terminal kinase-mediated autophagy pathway attenuates the anticancer activity of gemcitabine in human bladder cancer cells.
Topics: Anthracenes; Antimetabolites, Antineoplastic; Apoptosis; Autophagy; Cell Line, Tumor; Deoxycytidine; Enzyme Activation; Gemcitabine; Humans; JNK Mitogen-Activated Protein Kinases; Urinary Bladder Neoplasms | 2017 |